Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021

IF 25.2 1区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Lancet Public Health Pub Date : 2025-02-18 DOI:10.1016/s2468-2667(25)00009-x
{"title":"Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021","authors":"","doi":"10.1016/s2468-2667(25)00009-x","DOIUrl":null,"url":null,"abstract":"<h3>Background</h3>Decades of steady improvements in life expectancy in Europe slowed down from around 2011, well before the COVID-19 pandemic, for reasons which remain disputed. We aimed to assess how changes in risk factors and cause-specific death rates in different European countries related to changes in life expectancy in those countries before and during the COVID-19 pandemic.<h3>Methods</h3>We used data and methods from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to compare changes in life expectancy at birth, causes of death, and population exposure to risk factors in 16 European Economic Area countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, and Sweden) and the four UK nations (England, Northern Ireland, Scotland, and Wales) for three time periods: 1990–2011, 2011–19, and 2019–21. Changes in life expectancy and causes of death were estimated with an established life expectancy cause-specific decomposition method, and compared with summary exposure values of risk factors for the major causes of death influencing life expectancy.<h3>Findings</h3>All countries showed mean annual improvements in life expectancy in both 1990–2011 (overall mean 0·23 years [95% uncertainty interval [UI] 0·23 to 0·24]) and 2011–19 (overall mean 0·15 years [0·13 to 0·16]). The rate of improvement was lower in 2011–19 than in 1990–2011 in all countries except for Norway, where the mean annual increase in life expectancy rose from 0·21 years (95% UI 0·20 to 0·22) in 1990–2011 to 0·23 years (0·21 to 0·26) in 2011–19 (difference of 0·03 years). In other countries, the difference in mean annual improvement between these periods ranged from –0·01 years in Iceland (0·19 years [95% UI 0·16 to 0·21] <em>vs</em> 0·18 years [0·09 to 0·26]), to –0·18 years in England (0·25 years [0·24 to 0·25] <em>vs</em> 0·07 years [0·06 to 0·08]). In 2019–21, there was an overall decrease in mean annual life expectancy across all countries (overall mean –0·18 years [95% UI –0·22 to –0·13]), with all countries having an absolute fall in life expectancy except for Ireland, Iceland, Sweden, Norway, and Denmark, which showed marginal improvement in life expectancy, and Belgium, which showed no change in life expectancy. Across countries, the causes of death responsible for the largest improvements in life expectancy from 1990 to 2011 were cardiovascular diseases and neoplasms. Deaths from cardiovascular diseases were the primary driver of reductions in life expectancy improvements during 2011–19, and deaths from respiratory infections and other COVID-19 pandemic-related outcomes were responsible for the decreases in life expectancy during 2019–21. Deaths from cardiovascular diseases and neoplasms in 2019 were attributable to high systolic blood pressure, dietary risks, tobacco smoke, high LDL cholesterol, high BMI, occupational risks, high alcohol use, and other risks including low physical activity. Exposure to these major risk factors differed by country, with trends of increasing exposure to high BMI and decreasing exposure to tobacco smoke observed in all countries during 1990–2021.<h3>Interpretation</h3>The countries that best maintained improvements in life expectancy after 2011 (Norway, Iceland, Belgium, Denmark, and Sweden) did so through better maintenance of reductions in mortality from cardiovascular diseases and neoplasms, underpinned by decreased exposures to major risks, possibly mitigated by government policies. The continued improvements in life expectancy in five countries during 2019–21 indicate that these countries were better prepared to withstand the COVID-19 pandemic. By contrast, countries with the greatest slowdown in life expectancy improvements after 2011 went on to have some of the largest decreases in life expectancy in 2019–21. These findings suggest that government policies that improve population health also build resilience to future shocks. Such policies include reducing population exposure to major upstream risks for cardiovascular diseases and neoplasms, such as harmful diets and low physical activity, tackling the commercial determinants of poor health, and ensuring access to affordable health services.<h3>Funding</h3>Gates Foundation.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"88 1","pages":""},"PeriodicalIF":25.2000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Public Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-2667(25)00009-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Decades of steady improvements in life expectancy in Europe slowed down from around 2011, well before the COVID-19 pandemic, for reasons which remain disputed. We aimed to assess how changes in risk factors and cause-specific death rates in different European countries related to changes in life expectancy in those countries before and during the COVID-19 pandemic.

Methods

We used data and methods from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to compare changes in life expectancy at birth, causes of death, and population exposure to risk factors in 16 European Economic Area countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, and Sweden) and the four UK nations (England, Northern Ireland, Scotland, and Wales) for three time periods: 1990–2011, 2011–19, and 2019–21. Changes in life expectancy and causes of death were estimated with an established life expectancy cause-specific decomposition method, and compared with summary exposure values of risk factors for the major causes of death influencing life expectancy.

Findings

All countries showed mean annual improvements in life expectancy in both 1990–2011 (overall mean 0·23 years [95% uncertainty interval [UI] 0·23 to 0·24]) and 2011–19 (overall mean 0·15 years [0·13 to 0·16]). The rate of improvement was lower in 2011–19 than in 1990–2011 in all countries except for Norway, where the mean annual increase in life expectancy rose from 0·21 years (95% UI 0·20 to 0·22) in 1990–2011 to 0·23 years (0·21 to 0·26) in 2011–19 (difference of 0·03 years). In other countries, the difference in mean annual improvement between these periods ranged from –0·01 years in Iceland (0·19 years [95% UI 0·16 to 0·21] vs 0·18 years [0·09 to 0·26]), to –0·18 years in England (0·25 years [0·24 to 0·25] vs 0·07 years [0·06 to 0·08]). In 2019–21, there was an overall decrease in mean annual life expectancy across all countries (overall mean –0·18 years [95% UI –0·22 to –0·13]), with all countries having an absolute fall in life expectancy except for Ireland, Iceland, Sweden, Norway, and Denmark, which showed marginal improvement in life expectancy, and Belgium, which showed no change in life expectancy. Across countries, the causes of death responsible for the largest improvements in life expectancy from 1990 to 2011 were cardiovascular diseases and neoplasms. Deaths from cardiovascular diseases were the primary driver of reductions in life expectancy improvements during 2011–19, and deaths from respiratory infections and other COVID-19 pandemic-related outcomes were responsible for the decreases in life expectancy during 2019–21. Deaths from cardiovascular diseases and neoplasms in 2019 were attributable to high systolic blood pressure, dietary risks, tobacco smoke, high LDL cholesterol, high BMI, occupational risks, high alcohol use, and other risks including low physical activity. Exposure to these major risk factors differed by country, with trends of increasing exposure to high BMI and decreasing exposure to tobacco smoke observed in all countries during 1990–2021.

Interpretation

The countries that best maintained improvements in life expectancy after 2011 (Norway, Iceland, Belgium, Denmark, and Sweden) did so through better maintenance of reductions in mortality from cardiovascular diseases and neoplasms, underpinned by decreased exposures to major risks, possibly mitigated by government policies. The continued improvements in life expectancy in five countries during 2019–21 indicate that these countries were better prepared to withstand the COVID-19 pandemic. By contrast, countries with the greatest slowdown in life expectancy improvements after 2011 went on to have some of the largest decreases in life expectancy in 2019–21. These findings suggest that government policies that improve population health also build resilience to future shocks. Such policies include reducing population exposure to major upstream risks for cardiovascular diseases and neoplasms, such as harmful diets and low physical activity, tackling the commercial determinants of poor health, and ensuring access to affordable health services.

Funding

Gates Foundation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1990-2021年欧洲国家预期寿命的变化:《2021年全球疾病负担研究》的原因和风险因素亚分析
欧洲人预期寿命几十年来的稳步增长从2011年左右开始放缓,早在2019冠状病毒病大流行之前,原因仍有争议。我们的目的是评估不同欧洲国家的风险因素和特定原因死亡率的变化与这些国家在COVID-19大流行之前和期间的预期寿命变化之间的关系。方法我们使用来自2021年全球疾病、伤害和风险因素负担研究的数据和方法,比较了16个欧洲经济区国家(奥地利、比利时、丹麦、芬兰、法国、德国、希腊、冰岛、爱尔兰、意大利、卢森堡、荷兰、挪威、葡萄牙、西班牙和瑞典)和4个英国国家(英格兰、北爱尔兰、苏格兰和威尔士)在三个时间段内出生时预期寿命、死亡原因和人口暴露于风险因素的变化:1990-2011年、2011-19年和2019-21年。使用既定的预期寿命具体原因分解方法估计预期寿命和死亡原因的变化,并与影响预期寿命的主要死亡原因的风险因素的汇总暴露值进行比较。所有国家在1990-2011年(总体平均0.23岁[95%不确定区间[UI] 0.23至0.24岁])和2011 - 2019年(总体平均0.15岁[0.13至0.16岁])期间的平均年预期寿命均有所改善。2011 - 2019年,除挪威外,所有国家的预期寿命改善率都低于1990-2011年,挪威的平均年预期寿命增长从1990-2011年的0.21岁(95%,从0.20到0.22)上升到2011 - 2019年的0.23岁(0.21到0.26)(差异为0.03岁)。在其他国家,这些时期之间的平均年改善差异从冰岛的- 0.01年(0.19年[95% UI 0.16至0.21]vs 0.18年[0.09至0.26])到英国的- 0.18年(0.25年[0.24至0.25]vs 0.07年[0.06至0.08])不等。2019-21年,所有国家的平均年预期寿命总体下降(总体平均- 0.18岁[95% UI - 0.22至- 0.13]),除了爱尔兰、冰岛、瑞典、挪威和丹麦的预期寿命略有改善,以及比利时的预期寿命没有变化外,所有国家的预期寿命都出现了绝对下降。在各国,1990年至2011年期间预期寿命改善最大的死因是心血管疾病和肿瘤。心血管疾病死亡是2011 - 2019年期间预期寿命改善减少的主要原因,呼吸道感染和其他COVID-19大流行相关后果导致的死亡是2019-21年期间预期寿命减少的原因。2019年心血管疾病和肿瘤导致的死亡可归因于高收缩压、饮食风险、吸烟、高低密度脂蛋白胆固醇、高BMI、职业风险、大量饮酒以及包括低体力活动在内的其他风险。暴露于这些主要危险因素的情况因国家而异,在1990-2021年期间,所有国家都观察到暴露于高BMI因素的趋势增加而暴露于烟草烟雾的趋势减少。2011年之后,预期寿命持续改善最好的国家(挪威、冰岛、比利时、丹麦和瑞典)是通过更好地维持心血管疾病和肿瘤死亡率的降低来实现的,主要风险暴露的减少是其基础,政府政策可能减轻了这些风险。2019-21年期间,五个国家的预期寿命持续延长,这表明这些国家为抵御COVID-19大流行做好了更好的准备。相比之下,2011年之后预期寿命改善速度最慢的国家,在2019-21年的预期寿命下降幅度最大。这些发现表明,改善人口健康的政府政策也能增强抵御未来冲击的能力。这些政策包括减少人口接触心血管疾病和肿瘤的主要上游风险,如有害饮食和缺乏体育活动,解决健康状况不佳的商业决定因素,并确保获得负担得起的保健服务。FundingGates基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lancet Public Health
Lancet Public Health Medicine-Public Health, Environmental and Occupational Health
CiteScore
55.60
自引率
0.80%
发文量
305
审稿时长
8 weeks
期刊介绍: The Lancet Public Health is committed to tackling the most pressing issues across all aspects of public health. We have a strong commitment to using science to improve health equity and social justice. In line with the values and vision of The Lancet, we take a broad and inclusive approach to public health and are interested in interdisciplinary research. We publish a range of content types that can advance public health policies and outcomes. These include Articles, Review, Comment, and Correspondence. Learn more about the types of papers we publish.
期刊最新文献
Oral health and diabetes: a systematic review and meta-analysis Effect of energy-efficient homes on residents' health: evidence from a natural experiment in the Netherlands Correction to Lancet Public Health 2026; published online Feb 6. https://doi.org/10.1016/S2468-2667(25)00324-X Correction to Lancet Public Health 2026; 11: e176–86 Baseline imbalance and convergent endpoints in the OurFutures Vaping trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1